Target-HTN
72 evidence topics · 8 sources
Objective
Primary objective: safety, efficacy, and dose selection
“To compare the safety and efficacy of lorundrostat, an aldosterone synthase inhibitor, with placebo, and characterize dose-dependent safety and efficacy to inform dose selection in future trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The Trial on the Safety and Efficacy of MLS-101 (Lorundrostat) in Patients With Uncontrolled Hypertension (Target-HTN) was designed to examine the safety and efficacy of lorundrostat at 5 different doses in participants with uncontrolled hypertension, with a specific aim of BP reduction among participants with obesity or suppressed renin.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company description of the trial objective
Location and study date
Registered locations and study dates
| Field | Quoted record |
|---|---|
| Study start (actual) | “2021-07-01” |
| Primary completion (actual) | “2022-09-07” |
| Study completion (actual) | “2022-10-07” |
| Other study ID number | “MLS-101-201” |
| Sponsor | “Mineralys Therapeutics Inc.” |
Study design
Randomized, placebo-controlled, dose-ranging design
“Randomized, placebo-controlled, dose-ranging trial among adults with uncontrolled hypertension taking 2 or more antihypertensive medications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this multicenter, prospective, randomized, placebo-controlled, dose-ranging, double-blind clinical trial among adults with uncontrolled hypertension” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered design details
| Field | Quoted record |
|---|---|
| Phase | “Phase 2” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple” |
| Primary purpose | “Treatment” |
Prescreening, placebo run-in, and 8-week treatment period
“Participants underwent 2 to 4 weeks of prescreening, a 2-week placebo run-in period to ensure eligibility, and then randomization and treatment for 8 weeks. A final visit was conducted 2 to 4 weeks following completion of the double-blind treatment (eFigure 1 in Supplement 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Single-blind placebo run-in by renin stratum
Two cohorts defined by plasma renin activity
“An initial cohort of 163 participants with suppressed plasma renin (plasma renin activity [PRA] ≤1.0 ng/mL/h) and elevated plasma aldosterone (≥1.0 ng/dL) were enrolled, with subsequent enrollment of 37 participants with PRA greater than 1.0 ng/mL/h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Interim analyses and discontinuation of the two lowest doses
“An independent data and safety monitoring board performed an interim analysis in January 2022, and randomization to the 2 lowest doses of lorundrostat (12.5 mg once daily and 12.5 mg twice daily) was discontinued due to lack of consistent meaningful reduction of BP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An additional interim analysis was performed following the last participant visit from cohort 1 and full enrollment of cohort 2 to guide dose selection in future studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Weekly visits and blood pressure measurement schedule
“Following randomization, all participants’ study visits were conducted at weeks 1 through 8.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Twenty-four-hour ambulatory BP monitoring was measured at baseline and once again prior to the 8-week visit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Trial oversight and sponsor role
“The trial protocol was designed by Mineralys Therapeutics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“An independent data monitoring committee oversaw patient safety. Cytel performed the statistical analysis, and the Cleveland Clinic Coordinating Center for Clinical Research (C5Research) independently confirmed the primary end-point analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Uncontrolled blood pressure on 2 or more antihypertensive medications
“Patients were eligible for trial enrollment if they were older than 18 years with a systolic automated office BP (AOBP) of 130 mm Hg or greater while taking 2 or more antihypertensive medications for at least 4 weeks at maximally tolerated doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Renin and aldosterone criteria for each cohort
“Cohort 1 of the study enrolled participants with suppressed plasma renin (plasma renin activity [PRA] ≤1.0 ng/mL/h) and serum aldosterone level of 1.0 ng/dL or greater based on morning measurements, while cohort 2 enrolled participants with PRA of greater than 1.0 ng/mL/h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Key exclusion criteria
“Key exclusion criteria included orthostatic hypotension, type 1 diabetes, concomitant use of an epithelial sodium channel inhibitor or MRA, estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m2, morning serum cortisol level of less than 3 µg/dL, serum sodium level of less than 135 mmol/L, or hemoglobin A1c of 9% or greater.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A systolic AOBP of 175 mm Hg or greater, diastolic BP of 100 mm Hg or greater, or serum potassium level greater than 5.2 mmol/L was exclusionary in cohort 1, whereas exclusion criteria in cohort 2 were a systolic AOBP greater than 160 mm Hg, diastolic BP greater than 100 mm Hg, or serum potassium level greater than 4.8 mmol/L.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered inclusion and exclusion criteria
“Background antihypertensive treatment of ≥ 2 drugs” (opens the source at this quote in a new tab)
“Serum cortisol ≥ 18 mcg/dL” (opens the source at this quote in a new tab)
“Subjects with body mass index > 40 kg/m2” (opens the source at this quote in a new tab)
“Strong CYP3A and CYP3A4 inducers” (opens the source at this quote in a new tab)
“Subjects who are night-shift workers” (opens the source at this quote in a new tab)
Treatment
Cohort 1: five lorundrostat regimens or placebo
Add-on to stable background antihypertensive therapy with morning dosing
Study outcomes
Rationale for using change in office systolic blood pressure as the primary endpoint
Primary endpoint: change in automated office systolic blood pressure at week 8
“The primary efficacy end point was change in systolic AOBP from baseline to the end of study week 8.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Efficacy assessment with AOBP (average of the last 2 of 5 unattended measurements using an automated oscillometric sphygmomanometer device after approximately 5 minutes of rest in a seated position) was measured weekly throughout the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered primary outcome measure
Blood pressure reduction as the basis of cardiovascular benefit
Systolic blood pressure reduction and major cardiovascular events
Unattended automated office blood pressure measurement
“AOBP can be performed with or without staff being present, which is referred to as attended and unattended AOBP, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Several studies have reported that BP measured with AOBP versus the auscultatory method is closer to awake out-of-office BP levels measured with ambulatory BP monitoring (ABPM).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because having an observer present when BP readings are obtained may lead to inaccurate values (eg, if the patient or observer is talking), it is preferred to have the patient in a room alone for BP measurements (ie, unattended AOBP).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Secondary efficacy endpoints
Registered secondary outcome measures
Safety, pharmacodynamic, and adverse events of special interest endpoints
“Additional safety and pharmacodynamic biomarker end points included changes in PRA, serum aldosterone, cortisol, potassium, and eGFR during the study. Prespecified adverse events of special interest were incidence of hyperkalemia with dose modification, hypotension with symptoms, and adrenal insufficiency.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Sample size rationale
“The study was designed to provide information regarding a safe and effective dose of lorundrostat for subsequent efficacy trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A sample size of 30 participants per group was estimated to provide the half-width of the 2-sided 90% CI of 3.8 mm Hg with a common standard deviation assumed to be 9 mm Hg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All analyses of cohort 2 of the study were exploratory in nature, and no formal sample size considerations were undertaken for this cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants screened and randomized
Registered enrollment
| Field | Quoted record |
|---|---|
| Enrollment (actual) | “200” |
Participants randomized and analyzed for the primary endpoint by group
Description of analysis sets
Full analysis set and safety population
“Analyses were based on the full analysis set, defined as all randomized participants who received at least 1 dose of study medication. A safety analysis population was defined as all participants who took at least 1 dose of study drug.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mixed-model repeated-measures primary analysis
“The primary efficacy analysis was performed using a mixed-model repeated-measures approach with fixed effects of categorical terms for treatment, week, and treatment by week interaction, and baseline systolic AOBP as a fixed continuous covariate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Analysis of the primary end point was repeated in each prespecified subgroup, and these analyses were considered exploratory.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Handling of intercurrent events
“The statistical analysis plan outlined intercurrent events (ICE) that would result in imputation of week 8 BP. Specifically, if rescue BP medications were initiated, the observed systolic BP at time of rescue medication initiation was imputed. Additionally, if participant withdrawal occurred before completion of the 8-week period for a treatment-related reason or worsening, the baseline systolic BP value was imputed as the week 8 measurement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Secondary analyses and multiplicity
“All secondary efficacy end-point analyses are considered supportive, and any inferential statistics are considered descriptive in nature. No adjustment for multiplicity was performed due to the phase 2 exploratory intent of the trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered analysis populations and cohort 2 comparison
Results
Participant disposition
Registered participant flow by group
| Disposition | Placebo, Part 1 | 12.5 mg BID, Part 1 | 25 mg BID, Part 1 | 12.5 mg QD, Part 1 | 50 mg QD, Part 1 | 100 mg QD, Part 1 | Placebo, Part 2 | 100 mg QD, Part 2 |
|---|---|---|---|---|---|---|---|---|
| Started | “30” | “22” | “30” | “23” | “28” | “30” | “6” | “31” |
| Completed | “29” | “18” | “28” | “18” | “26” | “27” | “6” | “30” |
| Not completed | “1” | “4” | “2” | “5” | “2” | “3” | “0” | “1” |
| Adverse event | “0” | “0” | “0” | “1” | “0” | “0” | “0” | “0” |
| Lost to follow-up | “0” | “1” | “1” | “2” | “0” | “1” | “0” | “0” |
| Not specified by investigator | “0” | “3” | “0” | “0” | “1” | “0” | “0” | “0” |
| Protocol violation | “1” | “0” | “1” | “1” | “0” | “1” | “0” | “0” |
| Withdrawal by subject | “0” | “0” | “0” | “1” | “1” | “1” | “0” | “1” |
Lowest-dose groups closed after the interim analysis
Intercurrent events by group
“In the primary analysis population of cohort 1, participants receiving lorundrostat had ICE as follows: 100 mg once daily: 1 had ICE type 1 (initiation of rescue medication; systolic BP that triggered rescue medication is imputed), 4 had ICE type 3 (withdrawal from treatment for treatment-related reason or worsening; baseline systolic BP is imputed), and 3 had ICE type 4 (withdrawal from treatment for non–treatment-related reasons; mixed-model repeated-measures estimate); 50 mg once daily: 1 had ICE type 1; 25 mg twice daily: 1 had ICE type 3 and 2 had ICE type 4; 12.5 mg twice daily: 1 had ICE type 3; and 12.5 mg once daily: 1 had ICE type 1, 4 had ICE type 3, and 4 had ICE type 4. In the placebo group, 1 had ICE type 1 and 1 had ICE type 4. In the primary analysis population of cohort 2 receiving lorundrostat, 2 had ICE type 1, 2 had ICE type 3, and 1 had ICE type 4.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Demographics and baseline blood pressure of randomized participants
“Among randomized participants, the mean age was 65.7 (SD, 10.2) years, 60% were women, 36% were Black or African American, and 48% were of Hispanic or Latino ethnicity. At the time of randomization, 48% of participants had a body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) of greater than 30 and 40% had type 2 diabetes. Three or more antihypertensive medications were taken by 42% of the study population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cohort 1 participants had a mean baseline systolic AOBP of 142.2 (SD, 12.5) mm Hg and a mean diastolic AOBP of 81.5 (SD, 9.7) mm Hg, whereas cohort 2 participants had a mean baseline systolic BP of 139.1 (SD, 8.7) mm Hg and diastolic BP of 79.1 (SD, 9.7) mm Hg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics by group
Registered age distribution and region of enrollment
| Characteristic | Total (200 participants) |
|---|---|
| Age younger than 65 years | “83” |
| Age 65 to 79 years | “104” |
| Age 80 years or older | “13” |
| Enrolled in the United States | “200” |
| Body mass index, mean (SD), kg/m^2 | “31.1(5.0)” |
| Seated automated office systolic blood pressure, mean (SD), mmHg | “141.6(12.0)” |
Efficacy results
Primary end point: automated office systolic blood pressure at week 8
Placebo-subtracted change in systolic blood pressure with once-daily doses
“At week 8, the placebo group demonstrated a change of −4.1 (SE, 2.6) mm Hg in systolic AOBP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the once-daily dose cohorts, the placebo-subtracted change in systolic AOBP was −1.5 mm Hg (90% CI, −8.3 to 5.3 mm Hg; P = .71) for 12.5 mg, −9.6 mm Hg (90% CI, −15.8 to −3.4 mm Hg; P = .01) for 50 mg, and −7.8 mm Hg (90% CI, −14.1 to −1.5 mm Hg; P = .04) for 100 mg. The change in BP demonstrated with the twice-daily doses, compared with placebo, showed similar BP reduction.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because cohort 2 was an exploratory end point, no formal statistical testing was performed comparing lorundrostat with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Observed changes in office systolic blood pressure in participants with suppressed renin
“Following 8 weeks of treatment in participants with suppressed PRA, changes in office systolic blood pressure of −14.1, −13.2, −6.9, and −4.1 mm Hg were observed with 100 mg, 50 mg, and 12.5 mg once daily of lorundrostat and placebo, respectively. Observed reductions in systolic blood pressure in individuals receiving twice-daily doses of 25 mg and 12.5 mg of lorundrostat were −10.1 and −13.8 mm Hg, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Topline placebo-adjusted reductions reported by Mineralys
Secondary end point: automated office diastolic blood pressure at week 8
“The 50-mg once-daily dose of lorundrostat decreased diastolic AOBP by 5.5 mm Hg compared with placebo (90% CI, −9.4 to −1.5 mm Hg; P = .02). Other doses did not demonstrate statistically significant lowering of diastolic AOBP compared with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Secondary end point: ambulatory 24-hour blood pressure
“Twenty-four-hour ambulatory BP monitoring results including mean overnight and central systolic BP as assessed by pulse-wave velocity are reported in eTables 3 and 4 in Supplement 2.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Measure | Placebo, Part 1 | 12.5 mg BID, Part 1 | 25 mg BID, Part 1 | 12.5 mg QD, Part 1 | 50 mg QD, Part 1 | 100 mg QD, Part 1 | Placebo, Part 2 | 100 mg QD, Part 2 |
|---|---|---|---|---|---|---|---|---|
| Participants analyzed | “26” | “16” | “26” | “15” | “28” | “24” | “0” | “27” |
| Change in 24-hour mean SBP, least squares mean (SE), mmHg | “-1.01(2.38)” | “-5.78(3.03)” | “-9.05(2.38)” | “-2.51(3.15)” | “-4.86(2.34)” | “-6.34(2.5)” | Not reported | “-1.02(2.64)” |
| Change in 24-hour mean DBP, least squares mean (SE), mmHg | “-0.90(1.46)” | “-5.14(1.85)” | “-6.03(1.45)” | “-2.34(1.91)” | “-3.64(1.40)” | “-6.14(1.51)” | Not reported | “-0.07(1.69)” |
Secondary end point: blood pressure below 130/80 mm Hg at week 8
Exploratory subgroups: obesity and thiazide-type diuretic use
“Most notably, participants with obesity demonstrated greater BP lowering in response to lorundrostat. Individuals with a BMI greater than 30 randomized to 50 mg once daily of lorundrostat demonstrated a −16.7 mm Hg (90% CI, −25.5 to −7.9 mm Hg) change in systolic AOBP compared with placebo. With 100 mg once daily of lorundrostat, participants with obesity saw a −12.3 mm Hg (90% CI, −21.6 to −3.1 mm Hg) change in systolic AOBP compared with placebo. Among individuals with a BMI of 25 to 30, the BP changes were 2.2 mm Hg (90% CI, −7.4 to 11.8 mm Hg) and −4.5 (90% CI, −14.5 to 5.5 mm Hg) for the 50-mg and 100-mg once-daily doses, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, participants taking a thiazide-type diuretic randomized to 50 mg or 100 mg once daily of lorundrostat demonstrated changes of −12.9 mm Hg (90% CI, −21.2 to −4.7 mm Hg) and −10.0 mm Hg (90% CI, −21.2 to −1.6 mm Hg) in systolic AOBP compared with placebo. Blood pressure decreases were attenuated among participants not taking a diuretic (eTable 1 in Supplement 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exploratory cohort 2: participants without suppressed renin
“Participants with PRA of greater than 1.0 ng/mL/h (cohort 2) randomized to 100 mg once daily of lorundrostat demonstrated a similar change in mean systolic AOBP of −11.4 (SD, 2.5) mm Hg compared with those randomized to 100 mg once daily with suppressed plasma renin in cohort 1. The least-squares mean systolic AOBP difference between the 100-mg once-daily cohorts was 0.74 mm Hg (90% CI, −5.4 to 6.9 mm Hg).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacodynamic biomarkers: aldosterone, renin activity, and cortisol
“Lorundrostat resulted in reductions in serum aldosterone at all doses, whereas the cohort 1 placebo group saw an increase in mean serum aldosterone level of 0.14 (SD, 3.68) ng/dL. The 12.5-mg, 50-mg, and 100-mg once-daily doses in cohort 1 reduced mean serum aldosterone by 1.05 (SD, 4.33) ng/dL, 2.56 (SD, 3.72) ng/dL, and 2.88 (SD, 4.44) ng/dL, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In cohort 2, 100 mg daily of lorundrostat decreased mean serum aldosterone by 1.19 (SD, 5.38) ng/dL. Anticipated increases in PRA were observed ranging between 0.78 (SD, 3.44) ng/mL/h to 4.65 (SD, 11.27) ng/mL/h in cohort 1, and there were small increases in serum cortisol (eTable 2 in Supplement 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Once-daily compared with twice-daily dosing
“The 50-mg once-daily dose of lorundrostat lowered office BP to a similar degree as the 100-mg once daily dose, but resulted in fewer adverse events, including fewer episodes of hyperkalemia. Lorundrostat has a relatively short half-life, and once-daily dosing resulted in a 25% lower mean change in serum potassium when 50 mg once daily was compared with 25 mg twice daily.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Deaths, serious adverse events, and overall adverse events
“No participant deaths occurred during the trial. Three serious adverse events occurred; only 1 was deemed treatment related. A participant randomized to 100 mg once daily of lorundrostat in cohort 2 had worsening of hyponatremia necessitating stopping the drug. A total of 110 participants (55%) experienced any adverse event during the trial (Table 3). Most adverse events were classified as mild by investigators.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One participant was identified with worsening of preexisting coronary artery disease and 1 participant was found to have metastatic cancer in their peritoneum.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events and serum potassium changes by group
Hyperkalemia and hypotension
“Prespecified adverse events of special interest included 3 participants (2%) with hypotension. Mean serum potassium increases were similar across all lorundrostat doses, including increases of 0.25 mmol/L in the 50-mg and 100-mg once-daily groups. Six participants (3.6%) had serum potassium levels above 6.0 mmol/L during the trial (Table 3). No instances of hyperkalemia required intervention beyond discontinuation or reduction in the dose of lorundrostat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Affected individuals were counted once at highest-grade abnormality. Hemolyzed blood samples with serum potassium levels that were not reproducible on repeat testing were not included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cortisol and adrenal function
“No adrenocortical insufficiency occurred during the trial. Cosyntropin stimulation testing in participants randomized to 100 mg once daily in both cohort 1 and cohort 2 was normal, with stimulated values of cortisol greater than 18 µg/dL in all individuals receiving cosyntropin (eFigure 4 in Supplement 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Estimated glomerular filtration rate
“Declines in eGFR paralleled the reduction in systolic AOBP and were consistent with expected lowering of intraglomerular pressures (eTable 2 in Supplement 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Examples of more prevalent adverse events included hyperkalemia and decline in estimated glomerular filtration rate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered serious and other adverse events by group
Company summary of potassium findings
Study limitations
Summary
Target-HTN was a phase 2, dose-ranging trial that randomized 200 participants at sites in the United States to five lorundrostat regimens or placebo for 8 weeks, with no adjustment for multiplicity and with treatment differences reported as 90% confidence intervals. In cohort 1, the primary analysis included 19 to 29 participants per group, and the authors state that “each studied dose had a limited sample size”. Randomization to the 12.5 mg once-daily and 12.5 mg twice-daily groups stopped after the January 2022 interim analysis, and two interim analyses were performed in total. Cohort 1 enrolled only participants with suppressed renin; cohort 2 (37 participants, 6 receiving placebo) was exploratory, with no formal statistical testing against placebo. Sustained hypertension was not confirmed by 24-hour ambulatory monitoring before randomization, which the authors associate with “a prominent white-coat effect” in the 50 mg once-daily group. Participants with an eGFR below 60 mL/min/1.73 m2, or with serum potassium above 5.2 mmol/L (cohort 1) or 4.8 mmol/L (cohort 2), were excluded. The registered results define the proportion at goal as blood pressure of 130/80 mmHg or lower at week 8, while the publication describes it as below 130/80 mm Hg at week 7 or 8. The trial protocol was designed by the sponsor, Mineralys Therapeutics, which also provided input on the manuscript.
Limitations stated by the authors
“This trial has limitations. First, multiple dosing regimens were tested for efficacy, and each studied dose had a limited sample size. Second, 24-hour ambulatory BP monitoring was not used to confirm sustained hypertension before randomization, and this resulted in a disproportionate percentage of participants with a prominent white-coat effect in the 50-mg once-daily lorundrostat group. Third, cohort 1 of this trial selected participants with suppressed renin at baseline.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fourth, 2 interim analyses were performed; multiple interim analyses would not be appropriate in subsequent confirmatory trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Need for confirmatory studies
Sponsor role in the protocol and manuscript
“The trial protocol was designed by Mineralys Therapeutics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The first author (L.J.L.) wrote the first version of the manuscript and made revisions following input from coauthors and the sponsor.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote